FCGR3B eiwit (C-His, mens)

FCGR3B

CD16, CD16-I, CD16A, CD16b, FCG3, FcgammaRIIIb, FCGR3, FCGR3A, FCR-10, FCRIII, FCRIIIb, IGFR3

C-His

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS (Routinely tested) .

1. Loaded Recombinant Human CD16b / FCGR3B Protein (NA2 allotype, His Tag, ) (Cat: 11046-H08H) on His1K Biosensor, can bind anti-VEGFA (Research grade Bevacizumab Biosimilar) with an affinity constant of 8.3 μM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested) . 2. Recombinant Human IgG1-Fc Protein (103 Cys/Ser) (Cat: 10702-HNAH) captured on ProA chip, can bind Recombinant Human CD16b / FCGR3B Protein (NA2 allotype, His Tag, ) (Cat: 11046-H08H) with an affinity constant of 0.22 μM as determined in an SPR assay (Biacore T200) (Routinely tested) . 3. Recombinant Human CD16b / FCGR3B Protein (NA2 allotype, His Tag, ) (Cat: 11046-H08H) captured on CM5 Chip via Anti-his antibody chip, can bind anti-CD20 (Research grade Rituximab Biosimilar) with an affinity constant of 2.8 μM as determined in an SPR assay (Biacore 8K) (QC tested) .

Met1-Ser200

The recombinant human CD16b comprises 195 amino acids with a predicted molecular mass of 22.2 kDa. As a result of glycosylation, rh CD16b migrates as an approximately 46 kDa band in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 33-43 kDa verified by SEC-MALS (Routinely tested) .

Human